Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
On Wednesday, BTIG analyst Julian Harrison maintained a Buy rating on Tvardi Therapeutics Inc (NASDAQ:TVRD) with a steady price target of $55.00. The stock, currently trading at $33.39, has shown remarkable momentum, gaining nearly 83% over the past six months. According to InvestingPro data, analyst targets range from $39 to $65, with a strong consensus Buy recommendation. The company maintains excellent financial health, holding more cash than debt on its balance sheet. Tvardi, a biopharmaceutical company with a market capitalization of $313 million, has recently completed enrollment for its Phase 2 trial of TTI-101 in treating Idiopathic Pulmonary Fibrosis (IPF), a market currently valued at approximately $5 billion. This completion solidifies the expected timeline for 12-week data, which is now anticipated in the fourth quarter of 2025, a more precise forecast compared to the previous expectation of the second half of 2025. For deeper insights into Tvardi’s financial health and growth prospects, InvestingPro subscribers can access comprehensive research reports and additional ProTips.
Harrison noted the significance of the trial, suggesting that TTI-101 could emerge as the first treatment option in IPF that potentially reverses disease progression, rather than merely slowing it down. The current standard of care for IPF includes therapies that decelerate functional decline but are associated with high discontinuation rates due to adverse effects. While trading near its 52-week high of $34.31, InvestingPro analysis suggests the stock is currently in overbought territory, with analysts not anticipating profitability this year.
The analyst underscored the potential for TTI-101 by highlighting the scarcity of STAT3 inhibitors in development for IPF in the United States. He also pointed to the possibility of positive interim results from the trial, particularly changes in Forced Vital Capacity (FVC) — a measure of lung function that typically does not improve in untreated IPF patients and seldom improves with current treatments.
Furthermore, Harrison expressed optimism about the drug’s differentiated mechanism, which is expected to avoid intolerable safety adverse events (AEs). He anticipates that the stock will gain strength as the market begins to recognize the potential of TTI-101 in treating IPF, especially ahead of the forthcoming Phase 2 data. Harrison’s reiteration of the Buy rating reflects confidence in the drug’s prospects and its potential impact on the company’s valuation.
In other recent news, Tvardi Therapeutics has been the focus of multiple analyst reports and corporate developments. Oppenheimer initiated coverage on Tvardi with an Outperform rating and a price target of $65, highlighting the potential of TTI-101, a STAT3 inhibitor, in treating idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). BTIG also began coverage, assigning a Buy rating and a $55 price target, noting Tvardi’s pioneering role in STAT3 inhibitors for fibrotic diseases. Lucid (NASDAQ:LCID) Capital Markets issued a Buy rating with a $42 price target, citing the anticipated impact of TTI-101 in the IPF market.
In corporate developments, Cara Therapeutics, soon to be known as Tvardi Therapeutics, announced a 1-for-3 reverse stock split, consolidating shares and adjusting stock options. This follows the approval of a merger between Cara and Tvardi, with Tvardi becoming a wholly-owned subsidiary. Stockholders also approved new equity and stock purchase plans to incentivize employees post-merger. These developments are part of Cara’s strategic plan to enhance shareholder value and support future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.